The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a patent dispute in India.

An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s obesity and diabetes drugs, ahead of global patent expiries in 2026.

Vikrant Shrotriya, Novo Nordisk India MD responds to questions on future pricing, generics competition post patent expiry in March, Indian-specific pricing, demand in India & quality. “India is not a small country.

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)In the STEP UP programme, people with obesity taking Wegovy® 7.

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus Research to Hold from Buy on December 8th, The Fly reported.

Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair of failed trials, saying that patients showed a biological response in a handful of areas despite getting no cognitive improvement.

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients. Semaglutide is Novo Nordisk's largest growth driver, and it has not performed as well as expected in recent quarters. With a lower price for many consumers, the company could experience even lower top-line growth.